NeuroMetrix Reports Publication of Study Validating DPNCheck® Staging of Diabetic Peripheral Neuropathy Severity
September 01 2020 - 1:00PM
NeuroMetrix, Inc. (Nasdaq: NURO) today reported the
publication of a large study demonstrating that DPNCheck
effectively determines the severity of diabetic peripheral
neuropathy (DPN). DPNCheck is a widely used point-of-care
test that provides fast, accurate and cost-effective screening,
diagnosis and monitoring of peripheral neuropathies. It is
often used to stage the severity of DPN, which is the most common
specific cause of peripheral nerve disease and a ubiquitous
long-term complication of diabetes that may lead to foot ulcers and
amputation.
The publication in the Journal of Diabetes Investigation is
titled "A point‐of‐care nerve conduction device predicts the
severity of diabetic polyneuropathy: a quantitative but easy‐to‐use
prediction model" and is available at
https://onlinelibrary.wiley.com/doi/abs/10.1111/jdi.13386.
The study by Dr. Hideki Kamiya and colleagues evaluated 375
individuals with Type II diabetes at Aichi Medical University
Hospital (Nagakute, Japan). Each subject was evaluated with
the DPNCheck device and a gold standard nerve conduction study
(NCS) using traditional electromyography equipment. DPN
severity was graded using an NCS based classification system.
DPNCheck effectively identified subjects with moderate to severe
DPN (area under ROC of 0.87) and early signs of nerve dysfunction
(area under ROC 0.83).
“This large and well-designed study demonstrates that DPNCheck
effectively stages DPN severity. It also contributes to the
growing body of research that validates the technical and
diagnostic accuracy of DPNCheck and adds to its credibility as a
screening and diagnostic tool for DPN and peripheral neuropathy in
general,” said Shai N. Gozani, M.D., Ph.D., President and CEO
of NeuroMetrix.
About DPNCheck
DPNCheck is an automated, fast, accurate, and quantitative nerve
conduction test used to evaluate peripheral
neuropathies. It is designed to be used by clinicians at the
point-of-care to objectively detect, stage, and monitor peripheral
neuropathies. Please visit at www.dpncheck.com
About NeuroMetrix
NeuroMetrix is a leading developer and manufacturer of
diagnostic and therapeutic neurostimulation-based medical devices
that are used throughout the world. The Company has three FDA
cleared commercial products. DPNCheck® is a
point-of-care test that is used to evaluate peripheral
neuropathies. ADVANCE™ is a point-of-care device that
provides nerve conduction studies as an aid in diagnosing and
evaluating patients suspected of having focal or systemic
neuropathies. Quell® 2.0 is a wearable, mobile app
enabled, neurostimulation device indicated for symptomatic relief
and management of chronic pain and is available
over-the-counter. For more information,
visit NeuroMetrix.com.
NeuroMetrix, Inc. Thomas T. Higgins, 781-314-2761 SVP and Chief
Financial Officer neurometrix.ir@neurometrix.com
Source: NeuroMetrix, Inc.
NeuroMetrix (NASDAQ:NURO)
Historical Stock Chart
From Aug 2024 to Sep 2024
NeuroMetrix (NASDAQ:NURO)
Historical Stock Chart
From Sep 2023 to Sep 2024